ReviewCurrent opinion in lipidology2010
High-density lipoprotein heterogeneity and function in reverse cholesterol transport.
Review in Current opinion in lipidology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 171 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
171 citing papers in PubMed, 329 citations in OpenAlex.
- Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients.Scientific reports · 2017Trial
- Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Cholesterol and Albumin as Key Modulators of ICG Photostability in Aqueous Solution.Molecules (Basel, Switzerland) · 2026Article
- ABCA1-Mediated Structural Diversity of HDL Subspecies and Their Proposed Roles in Cardioprotection.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- HDL dysfunction: a role in the pathogenesis of cardiometabolic syndrome in chronic HIV infection?Metabolism: clinical and experimental · 2026Review
- Association Between High-Density Lipoprotein Characteristics and Hemostatic Parameters in the Netherlands Epidemiology of Obesity (NEO) Study-Brief Report.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Optimizing cardiovascular disease diagnosis through machine learning models integrating oxidized low-density lipoprotein and routine clinical indicators.Frontiers in endocrinology · 2026Article
- Narrative review on decoding the crosstalk between lipid homeostasis and immune pathways in membranous nephropathy.BMC nephrology · 2025Review
- High-density lipoprotein cholesterol and kidney disease progression in patients with type 2 diabetes mellitus: the Fukushima Cohort Study.BMJ open diabetes research & care · 2025Observational
- Mao Jian Black Tea Ethanol Extract Alleviates Alcoholic Liver Injury in Mice via Regulation of the PI3K/Akt/NF-κB Signaling Pathway.Foods (Basel, Switzerland) · 2025Article
- High-density lipoproteins. Part 2. Impact of disease states on functionality.American journal of preventive cardiology · 2025Article
- Low HDL-The Challenge.Clinical medicine & research · 2025Review
- Impact of serum uric acid to high-density lipoprotein cholesterol ratio on short-term outcomes in acute decompensated heart failure: a cohort study in Jiangxi Province, China.Frontiers in endocrinology · 2025Article
- Understanding the heterogeneity and dysfunction of HDL in chronic kidney disease: insights from recent reviews.BMC nephrology · 2024Review
- Schisandrin A inJournal of microbiology and biotechnology · 2024Article
- High density lipoprotein: When to rethink too much of a good thing.American journal of preventive cardiology · 2023Article
- Effects of Ethanolic and Aqueous Extracts ofNutrients · 2023Article
- Very low HDL levels: clinical assessment and management.Archives of endocrinology and metabolism · 2023Review
- Activated cholesterol metabolism is integral for innate macrophage responses by amplifying Myd88 signaling.JCI insight · 2022Article
- The HDL particle composition determines its antitumor activity in pancreatic cancer.Life science alliance · 2022Article
111 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewHDL is a cardioprotective lipoprotein, at least in part, because of its ability to mediate reverse cholesterol transport (RCT). It is becoming increasingly clear that the antiatherogenic effects of HDL are not only dependent on its concentration in circulating blood but also on its biological 'quality'. This review summarizes our current understanding of how the biological activities of individual subclasses of HDL particles contribute to overall HDL performance in RCT. RECENT
findingsRecent work indicates that apolipoprotein A-I-containing nascent HDL particles are heterogeneous and that such particles exert different effects on the RCT pathway. RCT from macrophages has been examined in detail in mice and the roles of plasma factors (lecithin-cholesterol acyltransferase, cholesterol ester transfer protein, phospholipid transfer protein) and cell factors (ATP-binding cassette transporter A1, ATP-binding cassette transporter G1, scavenger receptor class B type 1) have been evaluated. Manipulation of such factors has consistent effects on RCT and atherosclerosis, but the level of plasma HDL does not reliably predict the degree of RCT. Furthermore, HDL cholesterol or apolipoprotein A-I levels do not necessarily correlate with the magnitude of cholesterol efflux from macrophages; more understanding of the contributions of specific HDL subspecies is required. SUMMARY: The antiatherogenic quality of HDL is defined by the functionality of HDL subspecies. In the case of RCT, the rate of cholesterol movement through the pathway is critical and the contributions of particular types of HDL particles to this process are becoming better defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.